

Announcement of granting Nichirei Biosciences Inc. the rights to manufacture and sell the antibodies  
for use in pathological examination and research

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, “OncoTherapy”) announces that OncoTherapy and Nichirei Biosciences Inc. (President : Takashi Nakamura; hereinafter, “Nichirei Bio”) have agreed that OncoTherapy grants Nichirei Bio the non-exclusive rights to manufacture and sell the antibodies, which OncoTherapy established, for use in pathological examination and research, and executed the agreement today.

OncoTherapy will receive royalties calculated based on the sales of the antibodies from Nichirei Bio in consideration of the rights given to Nichirei Bio under this agreement.

< Nichirei Biosciences Inc.>

Nichirei Biosciences Inc. is a bioscience company which provides high-quality products and services in the field of cell-biology and functional materials. Nichirei Biosciences Inc. provides the products related to pathological examination and research including in vitro diagnostic (IVD) products such as Histofine® HER2 Kit (MONO).

Head Office: 6-19-20 Tsukiji, Chuo-ku, Tokyo 104-8402 Japan  
Main Business Activities: Manufacture and sales of IVD products, reagents, cosmetics and cosmetic materials, sales of animal sera and media for cell culture.  
Capital: 450 million Yen